Budget impact of adding one dipeptidyl peptidase-4 inhibitor to Ministry of Health Jordan tender list in the treatment of type II diabetes mellitus

الملخص EN

Total health expenditure in Jordan accounted for 7.72% of the Jordanian GDP in 2011 in which about one third is spent on pharmaceuticals.

Number of people with type2 diabetes is increasing in every country, in Jordan; the prevalence of diabetes in adult's ≥25 years of age is 17.1%, while an additional 7.8% of Jordanians have impaired glucose tolerance.

The aim was to investigate the impact of adding one DPP-4 inhibitor as an oral hypoglycemic agent to the tender list of Jordanian MoH in the treatment of Type II DM.

Quantities purchased by MoH in 2010 for oral hypoglycemic agents were used to calculate how many patients will be treated using these quantities.

Annual cost of treating hypoglycaemia caused by oral hypoglycemics and their current acquisition cost were estimated.

Costs of treating adverse effects were estimated based on MoH prices.

Private pharmacy retail price for Vildaglaptin was used to estimate budget impact of adding this DPP-4 inhibitor to the treatment options for DM patients in the public sector.

It was concluded that budget impact of adding Vildaglaptin to the tender list of MoH seems to have a very good potential of savings that is badly needed to treat more DM patients.